key: cord-0706210-m8ujn7m5
authors: Al-Namaeh, Mashael
title: COVID-19 and conjunctivitis: a meta-analysis
date: 2021-03-25
journal: Ther Adv Ophthalmol
DOI: 10.1177/25158414211003368
sha: ce52dfb63bb846a374d3c5235f1acb6b6aa8f9b0
doc_id: 706210
cord_uid: m8ujn7m5

COVID-19 is a disease first identified in Wuhan City, Hubei Province, China, in December 2019, causes by a SARS-COV-2 virus infection. By 27 October 2020, 43,921,473 confirmed cases were reported worldwide, with 1,166,389 COVID-19 deaths. Conjunctivitis has been reported in adults and pediatric patients with COVID-19. OBJECTIVE: The aim of this meta-analysis is to estimate the odd Ratio (ORs) of conjunctivitis in patients with COVID-19. METHODS: A systematic review and meta-analysis have been performed using the PubMed and Google Scholar literature search. The ORs of conjunctivitis in adults and pediatric patients is the outcome of this meta-analysis. RESULTS: There have been 1041 articles published since the outbreak in December 2019, according to the latest literature. For the meta-analysis, 20 studies with a total of 3383 participants were included. The odds ratio (ORs) of conjunctivitis was 0.01 (95% confidence interval [CI]: 0.00–0.02). No bias has been reported. CONCLUSION: Conjunctivitis is the most common ocular manifestations reported in adults. This comprehensive meta-analysis quantifies the existing evidence linking conjunctivitis with COVID-19 and highlights the high percentage of heterogeneity that is shown in the current studies. Finally, it offers a single review article which includes all the current articles available for COVID-19 and conjunctivitis in adults and children.

The standards and guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) has been followed. 5, 6 PubMed search and other search engines "Google Scholar" have been used from December 2019 to 27 October 2020. The key words used were "COVID-19," "Conjunctivitis" used individually or in combination. We selected randomized trials, observational studies, case series or case reports, and letters of research, letters to editors for confirmed cases of COVID-19 for the literature review, but only retrospective studies and observational studies for the meta-analysis. According to current scientific literature since the outbreak in December 2019 there have been 1041 papers written. The selected studies applied no language or other restrictions.

For bias detection, in each eligible study, a 7-point predefined quality control was used. The corresponding risk of bias was categorized as low (L), high (H), or unknown (U) to each quality item according to Higgins and colleagues 5, 7 Unknown is used to judge insufficient information. The Complete outcome data were judged as "Low risk" or "high risk" or "unknown." The "low risk" is used when follow up percentage of participants lost was lower than 5% and "high risk" when follow up loss percentage was more than 20%. 8, 9 For other potential sources of bias, including the bias source, including the funding source reported in each protocol, the term "other bias" was used. 5, 10 The overall treatment effect was calculated and the study weight for each study was calculated. Due to the larger sample size of some of the studies, the study weight was calculated and the "true effect" for each study is shown. The larger sample size provides more information than a small sample size.

(a) COVID-19 patients. (b) Conjunctivitis was assessed, and the number of events was reported.

Exclusion criteria a) If no data on ocular, manifestations neither conjunctivitis b) Animal research c) Case report, letter to the editorial or review

Quality of the comparative studies. Assessment of the quality characteristics used the following criteria: (1) random sequence generation (R), (2) allocation concealment (A), (3) blinding of participants and personnel (PB), 4) Blinding of outcome assessment (DB), (5) Incomplete outcome data (Attrition Bias) (AB), 6) Selective reporting (Reporting bias) (RB), and 7) Other bias (O).

Each study was labeled with the right item either adequate (low risk of bias), unclear (unknown risk of bias), and inadequate (high risk of bias).

One researcher independently screened the articles.

MedCalc 16.4.3 (Ostend, Belgium) software was used to statistically analyze the data and REV5. The ORs were calculated in each study. The study heterogeneity was assessed with the Cochran Q and I 2 statistics. For the heterogeneity qualitative interpretation, I 2 values of at least 50% were considered to reflect considerable heterogeneity, while values of at least 75% indicated large heterogeneity, as per the Cochrane Handbook. 5 Publication bias was evaluated using both graphical funnel plot 11 and Beggs statistical test. Random-effect model was used.

PubMed and Google Scholar Searches of database resulted in 8681 articles; 1041 results were screened after duplicates removal. For the metaanalysis reviewer, 20 articles were analyzed with a total of 3383 participants. Eighteen articles were studied in adult patients with COVID-19 and two articles were studied in pediatric patients with COVID-19. 12, 13 The flow chart presenting the selection of eligible studies is summarized (Figures 1 and 2 ). The characteristics of the included studies are summarized (Table 1) . The ORs ranged from 0.00 to 5.17, which reveals the high heterogeneity between individual studies. The sample size also varied between 17 and 1099 COVID-19 patients ( Figure 2 ).

The risk of bias of the included studies has been reviewed and studied by the author (Supplemental Table 1 ). Random sequence was low in 6 studies. 12, 14, 19, 20, 22, 27 Allocation concealment was low in five studies. 12, 14, 20, 22, 27 The blinding participants and personnel (PB) is low in 10 articles. 12, [20] [21] [22] [26] [27] [28] [30] [31] [32] The blinding of outcome assessment (DB) is low in 12 articles. 12, [20] [21] [22] [24] [25] [26] [27] [28] [30] [31] [32] The incomplete outcome data (Attrition Bias) (AB) is low in 19 articles. [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] [31] [32] Selective reporting (Reporting bias (RB) is 16 articles. [12] [13] [14] [16] [17] [18] 20, 21, 24, [26] [27] [28] [29] [30] [31] [32] All other bias is low in all 20 articles 12-22,24-33 (Supplemental Table 1 ).

Overall final analyses. The systematic review of the selected 20 articles estimated the ORs of conjunctivitis of a total of 3383 COVD-19 patients. The ORs = 0.01; 95% confidence interval (CI): [0.00, 0.02] ( Figure 2 ). Heterogeneity was statistically significant using the I 2 value of 97% and p < 0.0001. In addition, no publication bias was detected using the funnel plot inspection.

Conjunctivitis may be the first manifestation of the COVID-19 infection. 15, 23, 34 Most patients in the 20 articles were hospitalized with COVID-19 (Table 2) . Each article had at least two groups of patients, both non-severe and severe. Other articles were grouped into three classes, moderate, severe, and critical according to the PC-NCP guidelines 35 (Table 2) .

The majority of patients with viral conjunctivitis were male patients (Table 3) . Other ocular manifestations have been documented, such as conjunctival hyperemia 25, 29, 31 and secretion, 25, 30 conjunctival discharge, 29,31 eye rubbing, subconjunctival bleeding, keratitis, and vitreous hemorrhages. Oruc and colleagues, recorded that 5% of COVID-19 patients had conjunctivitis and 5% had diplopia. 28 Acute conjunctivitis 21 and chronic conjunctivitis 22 were reported. Some studies reported conjunctivitis following the onset of COVID-19, [13] [14] [15] [16] [17] [18] [19] [20] 22, [24] [25] [26] [27] 29, 30, 32 while one study reported the diagnosis of conjunctivitis as the initial manifestation of COVID-19. 12 Guemes-Villahoz and colleagues 21 reported acute conjunctivitis in 13 patients prior to hospital admission, 12 patients between hospital admission and evaluation, and 10 patients at the time of evaluation. All of the included studies were hospitalized by COVID-19, except for one study included nonhospitalized patients. 31 All patients were laboratory-confirmed SARS-COV2.

One study confirms that conjunctivitis can be a symptom of COVID-19 infection related with more serious type of disease, which confirms previous study. 36 Furthermore, unilateral conjunctivitis in a 27-year-old COVID-19 male patient, has been reported as a first manifestation. 37 Only two patients with conjunctivitis had been reported in 72 laboratory-confirmed COVID-19 cases. 19 In addition, only one patient had conjunctivitis and foreign body sensation (2.3%) and tears in the 43 COVID-19 patients. 32 In contrast, other reports showed no ocular conjunctivitis which could be due to the very low sample size. 38 The prevalence rate of acute conjunctivitis in COVID-19 was reported ranging from 1.1 to 15.9. 15, 39 Other studies reported acute conjunctivitis in 31.6% of patients. 23, 39, 40 One meta-analysis study showed that the probability of conjunctivitis in patients with non-severe COVID-19 was 4 out of 173, and severe COVID-19 was 5 of 926. 40 Wu et al. 15 showed that only one patient had the first symptoms of conjunctivitis.

There is certainly a difference in the percentage of conjunctivitis in COVID-19 patients that contributes to the aim of this meta-analysis. In our study, we found that 1% of COVID-19 patients are likely to have conjunctivitis with a total of 3383 COVID-patients. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] [31] [32] A related point to consider is that these findings have been reviewed retrospectively, and second, clinical symptoms have not been confirmed by clinical tests, but only have been subjectively reported by patients. In addition, because conjunctival mucosa can be a point of entry of COVID-19 infection due to overexpression of ACE2 receptors in epithelium from congested conjunctiva, 41 careful attention should also be given to protective measures such as the face shields and goggles.

This meta-analysis is consistent with the metaanalysis that showed that the incidence of ocular manifestations in COVID-19 patients ranged from 2% to 32%. 42 This meta-analysis review studied ORs of conjunctivitis and showed that the ORs ranged from 0.00 to 0.02.

The limitation of this study is (1) pediatric COVID-patients studies are needed, only 2 of the 20 studies in which the pediatric study was conducted, (2) only one reviewer performed the meta-analysis which may lead to bias, and (3) a greater sample size is needed.

Viral conjunctivitis is the most common ocular manifestations reported in adults. This comprehensive meta-analysis quantifies the existing evidence linking conjunctivitis with COVID-19 and highlights the high percentage of heterogeneity that is shown in the current studies. Viral conjunctivitis has been reported in males more than females. Finally, it offers a single review article which includes all the current articles available for COVID-19 and conjunctivitis.

The coronavirus pandemic: what does the evidence show?

COVID-19 emergency in the cruise's ship: a case report of conjunctivitis

The ocular manifestations and transmission of COVID-19: recommendations for prevention

The ocular surface and the coronavirus disease 2019: does a dual "ocular route" exist?

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Evidence-based medicine and treatment choices

Evidence-based medicine

Why the Cochrane risk of bias tool should include funding source as a standard item

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China

Ocular manifestations and viral shedding in tears of pediatric patients with coronavirus disease 2019: a preliminary report

Clinical characteristics of coronavirus disease 2019 in China

Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva

Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients

The evidence of SARS-CoV-2 infection on ocular surface

Clinical profile and prevalence of conjunctivitis in mild COVID-19 patients in a tertiary care COVID-19 hospital: a retrospective cross-sectional study

Conjunctivitis in COVID-19 patients: frequency and clinical presentation

Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study

Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease

Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients

Evaluation of conjunctival swab PCR results in patients with SARS-CoV-2 infection

Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19

Assessment of the frequency and biochemical parameters of conjunctivitis in COVID-19 and other viral and bacterial conditions

Novel coronavirus pneumonia combined with conjunctivitis: three cases report

Ocular findings in patients with coronavirus disease 2019 (COVID-19) in an outbreak hospital

More than loss of taste and smell: burning watering eyes in coronavirus disease 2019

Detection of severe acute respiratory syndrome coronavirus-2 in the tears of patients with coronavirus disease 2019

Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography

Ocular manifestation as first sign of coronavirus disease 2019 (COVID-19): interest of telemedicine during the pandemic context

National Health Commission of the People's Republic of China. The guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP)

Conjunctivitis and COVID-19: a meta-analysis

Unilateral conjunctivitis as first presentation of coronavirus disease 2019 (COVID-19): a telemedicine diagnosis

Ocular manifestation, eye protection, and COVID-19

Extra-respiratory manifestations of COVID-19

Letter to the editor: are severe COVID-19 patients more susceptible to conjunctivitis

SARS-CoV-2 receptor ACE2 is expressed in human conjunctival tissue, especially in diseased conjunctival tissue

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid